TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10732932

Group type: EXPERIMENTAL
Intervention: Cardioembolic strokes
Number of subjects: 2885

Group type: EXPERIMENTAL
Intervention: Lacunar strokes
Number of subjects: 2885

Group type: EXPERIMENTAL
Intervention: Large-artery strokes
Number of subjects: 2885

Group type: EXPERIMENTAL
Intervention: Cardioembolic strokes in symptomatic artery territory
Number of subjects: 2885

Group type: EXPERIMENTAL
Intervention: Large-artery strokes in symptomatic artery territory
Number of subjects: 2885

Group type: EXPERIMENTAL
Intervention: Cardioembolic strokes in asymptomatic artery territory
Number of subjects: 2885

Group type: EXPERIMENTAL
Intervention: Lacunar strokes in asymptomatic artery territory
Number of subjects: 2885

Group type: EXPERIMENTAL
Intervention: Large-artery strokes in asymptomatic artery territory
Number of subjects: 2885

Group type: EXPERIMENTAL
Intervention: Strokes unrelated to carotid stenosis
Number of subjects: 2885
Study: 8629921

Group type: EXPERIMENTAL
Intervention: Ankle joint movement perception threshold (JMPT) assessment using a device designed for this study.
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Cutaneous sensory function measurement for vibration perception using a vibrometer and touch-pressure perception using Semmes-Weinstein monofilaments.
Number of subjects: 51
Study: 1444931

Group type: EXPERIMENTAL
Intervention: Amplitude-modulated noise (160 Hz)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Filtered-random noise (600 Hz)
Number of subjects: 100
Study: 6204202

Group type: EXPERIMENTAL
Intervention: Positive food challenges (up to 8 g of dehydrated food)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo challenges (60 total)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Negative food challenges (41 total)
Number of subjects: 33
Study: 30797120

Group type: EXPERIMENTAL
Intervention: Minority condition (one child eating raspberries)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition (no food presented)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Majority condition (all children eating raspberries)
Number of subjects: 0
Study: 29547834

Group type: EXPERIMENTAL
Intervention: Tailored FEC (E 75-90 mg/m2, C 900-1200 mg/m2)
Number of subjects: 1535

Group type: COMPARATOR
Intervention: Standard FEC (fluorouracil 600 mg/m2, epirubicin 60 mg/m2, cyclophosphamide 600 mg/m2)
Number of subjects: 1535

Group type: COMPARATOR
Intervention: Registered cohort (standard FEC for grade 3-4 leukopenia)
Number of subjects: 1535
Study: 26710243

Group type: EXPERIMENTAL
Intervention: Paritaprevir (300 mg)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Paritaprevir with ritonavir (multiple doses)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Paritaprevir (single dose)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study: 24898637

Group type: EXPERIMENTAL
Intervention: Neuropostural optimization (NPO) protocol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham protocol
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both NPO and Sham protocols
Number of subjects: 60
Study: 22576861

Group type: EXPERIMENTAL
Intervention: ProSeal (Reliance)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: CervitecPlus (Ivoclar Vivadent)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Maximum Cure® (Reliance)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: elmex® gelée (GABA)
Number of subjects: 75

Group type: COMPARATOR
Intervention: non-treated control group
Number of subjects: 75
Study: 20218761

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention including a brief presentation, brochure for parents, educational video, and sun protection incentives for children.
Number of subjects: 197

Group type: COMPARATOR
Intervention: Control group not specified in the abstract.
Number of subjects: 197
Study: 18833128

Group type: EXPERIMENTAL
Intervention: Haloinhalation therapy
Number of subjects: 125
Study: 16253904

Group type: EXPERIMENTAL
Intervention: LA circumferential ablation
Number of subjects: 80

Group type: COMPARATOR
Intervention: Nonencircling linear ablation
Number of subjects: 80
Study: 12161081

Group type: EXPERIMENTAL
Intervention: Journals promoting CONSORT
Number of subjects: 105

Group type: COMPARATOR
Intervention: Journals not promoting CONSORT
Number of subjects: 105
Study: 11783143

Group type: EXPERIMENTAL
Intervention: Prepared rhubarb
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nifedipine (Control)
Number of subjects: 0
Study: 7762505

Group type: EXPERIMENTAL
Intervention: Nicorandil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nitroglycerin (NTG)
Number of subjects: 0
Study: 2317421

Group type: EXPERIMENTAL
Intervention: EMLA cream applied for 90 minutes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EMLA cream applied for 120 minutes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EMLA cream applied for less than 120 minutes
Number of subjects: 0
Study: 387170

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 0
Study: 30553766

Group type: EXPERIMENTAL
Intervention: Exercise group (EX) performing a 20-min aerobic and coordinative exercise session on each school day for 8 weeks
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (CON) encouraged to have social interactions
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Exercise group (EX)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 36
Study: 27753157

Group type: EXPERIMENTAL
Intervention: Active stimulation (n=101)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Delayed activation control (n=35)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Combined group (baseline and 12-month comparisons)
Number of subjects: 136
Study: 26175226

Group type: EXPERIMENTAL
Intervention: NMES + cPR
Number of subjects: 27

Group type: COMPARATOR
Intervention: Sham + cPR
Number of subjects: 27
Study: 24099414

Group type: EXPERIMENTAL
Intervention: Falloon Psychoeducation Program (FPP)
Number of subjects: 340

Group type: COMPARATOR
Intervention: Family supportive therapy with generic information
Number of subjects: 340
Study: 20840875

Group type: EXPERIMENTAL
Intervention: Enrolled in clinical trials (cases)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Standard cancer treatments (controls)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Both groups (cases and controls)
Number of subjects: 184
Study: 18502382

Group type: EXPERIMENTAL
Intervention: Screening for abdominal aortic aneurysms (AAAs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Various screening methods
Number of subjects: 0
Study: 16223206

Group type: EXPERIMENTAL
Intervention: rifaximin 1,200 mg/day
Number of subjects: 18

Group type: COMPARATOR
Intervention: lactulose 10-20 g three times daily
Number of subjects: 18

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study: 12169045

Group type: COMPARATOR
Intervention: Desloratadine/Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Desloratadine/Ketoconazole
Number of subjects: 24
Study: 10550153

Group type: EXPERIMENTAL
Intervention: 13‐cis‐retinoic acid (13‐CRA) 30 mg orally daily for 6 months
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 7495926

Group type: EXPERIMENTAL
Intervention: Flumazenil 2 mg
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 2180267

Group type: EXPERIMENTAL
Intervention: Lovastatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fibrates
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control agents (cholestyramine, fibrates, probucol)
Number of subjects: 0
Study: 424477

Group type: EXPERIMENTAL
Intervention: alpha‐flupenthixol
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: beta‐flupenthixol
Number of subjects: 41

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: active medication (alpha‐flupenthixol)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: non-habituation of skin conductance
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: insidious onset (Feighner negative patients)
Number of subjects: 41
Study: 31199837

Group type: EXPERIMENTAL
Intervention: Parkinson's disease (PD)
Number of subjects: 6185
Study: 28953616

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (40 mg) administered 30 minutes before induction of anesthesia
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (40 mg) administered immediately after induction of anesthesia
Number of subjects: 136

Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 136
Study: 25704429

Group type: EXPERIMENTAL
Intervention: Bursectomy
Number of subjects: 210

Group type: COMPARATOR
Intervention: Nonbursectomy
Number of subjects: 210
Study: 23368980

Group type: EXPERIMENTAL
Intervention: Opioids (morphine, oxycodone)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Non-opioids (placebo)
Number of subjects: 35
Study: 21425574

Group type: EXPERIMENTAL
Intervention: Modified Qianyang Pellet (MQYP)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (basic treatment + fluid resuscitation)
Number of subjects: 48
Study: 19588638

Group type: EXPERIMENTAL
Intervention: Fixed-combination gel containing BPO 5% and clindamycin 1% (BPO/C) plus tretinoin microsphere gel 0.04% (RAM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fixed-combination gel containing clindamycin phosphate 1.2% and tretinoin 0.025% (CPT) plus a once-daily BPO 5% wash
Number of subjects: 0
Study: 17382640

Group type: EXPERIMENTAL
Intervention: Carpentier ring
Number of subjects: 356

Group type: COMPARATOR
Intervention: Duran ring
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 356
Study: 15069024

Group type: EXPERIMENTAL
Intervention: Nurse practitioners added to general practice teams
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (no nurse practitioners)
Number of subjects: 48
Study: 11177037

Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 9609934

Group type: EXPERIMENTAL
Intervention: Wavelet analysis of click-evoked otoacoustic emissions (CEOAE's)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Wavelet transform applied to CEOAE's
Number of subjects: 0
Study: 7813389

Group type: EXPERIMENTAL
Intervention: L-acetylcarnitine (LAC) 1500 mg/day for 90 days
Number of subjects: 481

Group type: COMPARATOR
Intervention: Placebo treatment for 30 days (phase T0) and further 30 days of placebo treatment (phase T3)
Number of subjects: 481
Study: 2898167

Group type: EXPERIMENTAL
Intervention: 300 mg ranitidine at night
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 150 mg ranitidine twice daily
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 40 mg famotidine at night
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 20 mg famotidine twice daily
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 30289098

Group type: EXPERIMENTAL
Intervention: Infographic promotion on social media
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (screen capture image of article’s abstract)
Number of subjects: 24
Study: 29133325

Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery (MISS) - mini-open decompression with bilateral interbody fusion and percutaneous pedicle screw fixation
Number of subjects: 184

Group type: COMPARATOR
Intervention: Open surgery - conventional surgery with decompression and instrumented fusion with pedicle screws and bilateral interbody fusion
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery (MISS)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 184
Study: 25752401

Group type: EXPERIMENTAL
Intervention: PET-based isotoxic accelerated radiation therapy (PET-ART)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Conventional fixed-dose CT-based radiation therapy (CRT)
Number of subjects: 200
Study: 24166906

Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 105
Study: 21406465

Group type: EXPERIMENTAL
Intervention: Short-term abstinence (3-30 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Long-term abstinence (3-24 months)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acute stress induced by the Trier Social Stress Test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg) administered 1 hour before stress
Number of subjects: 0
Study: 18201356

Group type: EXPERIMENTAL
Intervention: PUVA treatment twice/week
Number of subjects: 20

Group type: COMPARATOR
Intervention: PUVA treatment three times/week
Number of subjects: 20
Study: 15356084

Group type: EXPERIMENTAL
Intervention: DHEA (100 mg/d, 3 months)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: DHEA
Number of subjects: 36

Group type: COMPARATOR
Intervention: Estradiol (E)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Testosterone (T)
Number of subjects: 36
Study: 11458055

Group type: EXPERIMENTAL
Intervention: 3-month neoadjuvant hormonal therapy (7.5 mg leuprolide intramuscularly monthly and 250 mg flutamide orally 3 times daily)
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: 8-month neoadjuvant hormonal therapy (7.5 mg leuprolide intramuscularly monthly and 250 mg flutamide orally 3 times daily)
Number of subjects: 547

Group type: COMPARATOR
Intervention: 3-month neoadjuvant hormonal therapy
Number of subjects: 547

Group type: COMPARATOR
Intervention: 8-month neoadjuvant hormonal therapy
Number of subjects: 547
Study: 9558128

Group type: EXPERIMENTAL
Intervention: 1000 mg VPA daily
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 2000 mg VPA daily
Number of subjects: 16
Study: 8051603

Group type: EXPERIMENTAL
Intervention: Selected risk factors (prognosis, restricted activity days, presence of hearing and speech problems, perceived unpredictability of symptoms)
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Respondents' perceptions of the impact of the condition
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Psychiatric Symptom Index
Number of subjects: 286
Study: 2977273

Group type: EXPERIMENTAL
Intervention: Zoladex 3.6 mg depot
Number of subjects: 193

Group type: COMPARATOR
Intervention: Diethylstilbestrol (DES) 3 mg/day
Number of subjects: 193
Study: 28873028

Group type: EXPERIMENTAL
Intervention: Single intraoperative dose of IV acetaminophen
Number of subjects: 260

Group type: COMPARATOR
Intervention: Standard postoperative pain regimen (oral acetaminophen and ibuprofen)
Number of subjects: 260
Study: 27074894

Group type: EXPERIMENTAL
Intervention: TAP block with 40 mL of 0.375% levobupivacaine and morphine patient‐controlled analgesia
Number of subjects: 52

Group type: COMPARATOR
Intervention: Morphine patient‐controlled analgesia (Control)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: TAP block
Number of subjects: 52
Study: 25294064

Group type: EXPERIMENTAL
Intervention: Comprehensive child obesity intervention program
Number of subjects: 1860
Study: 23142302

Group type: EXPERIMENTAL
Intervention: Recombinant modified vaccinia Ankara (rMVA) and fowlpox (rFPV) with matched HIV-1 inserts
Number of subjects: 150

Group type: COMPARATOR
Intervention: Empty vectors (MVA and FPV)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: MVA (up to 5 administrations)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Two doses of MVA
Number of subjects: 150
Study: 19815652

Group type: EXPERIMENTAL
Intervention: Cisplatin-epirubicin-paclitaxel (PET)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Epirubicin-paclitaxel (ET)
Number of subjects: 200
Study: 18570984

Group type: EXPERIMENTAL
Intervention: Direct composite resin restoration without cuspal coverage
Number of subjects: 41

Group type: COMPARATOR
Intervention: Direct composite resin restoration with cuspal coverage
Number of subjects: 41
Study: 16200842

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 35

Group type: COMPARATOR
Intervention: Oral Contraceptive Pills (OCP)
Number of subjects: 35
Study: 11409855

Group type: EXPERIMENTAL
Intervention: Short-term ventilation tubes
Number of subjects: 187

Group type: COMPARATOR
Intervention: Watchful waiting
Number of subjects: 187
Study: 11367650

Group type: EXPERIMENTAL
Intervention: Huancongdan (HCD) capsule
Number of subjects: 72

Group type: COMPARATOR
Intervention: Hydergine
Number of subjects: 72
Study: 8156307

Group type: EXPERIMENTAL
Intervention: Etidronate (400 mg/day for 2 weeks, then 11 weeks off etidronate; four cycles total) + Prednisone
Number of subjects: 20

Group type: COMPARATOR
Intervention: Prednisone only
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Etidronate + Prednisone
Number of subjects: 20
Study: 3045423

Group type: EXPERIMENTAL
Intervention: Surgery plus Adriamycin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgery only
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjuvant CYVADIC chemotherapy (cyclophosphamide, vincristine, Adriamycin, and dacarbazine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjuvant VAC chemotherapy (vincristine, actinomycin-D, and cyclophosphamide)
Number of subjects: 0
Study: 31185942

Group type: EXPERIMENTAL
Intervention: Oxycodone 0.1 mg/kg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sufentanil 0.1 μg/kg
Number of subjects: 40
Study: 28407754

Group type: EXPERIMENTAL
Intervention: Audit and feedback with peer review
Number of subjects: 197

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 197
Study: 26856016

Group type: EXPERIMENTAL
Intervention: 1450 ppm fluoride as sodium monofluorophosphate (SMFP)/zinc‐based dentifrice
Number of subjects: 86

Group type: COMPARATOR
Intervention: 1450 ppm fluoride as sodium monofluorophosphate (SMFP)/zinc‐free dentifrice
Number of subjects: 86
Study: 23549409

Group type: EXPERIMENTAL
Intervention: Encapsulated oral supplement of Bifidobacterium infantis 35624
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study: 21760569

Group type: EXPERIMENTAL
Intervention: Enteric-coated mycophenolate sodium (EC-MPS)
Number of subjects: 113
Study: 19390464

Group type: EXPERIMENTAL
Intervention: Direct Optical Access (DOA)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Closed Veress Needle Approach
Number of subjects: 186
Study: 17126655

Group type: EXPERIMENTAL
Intervention: Hypothermic patients (oral body temperature <35.8 degrees C)
Number of subjects: 319

Group type: COMPARATOR
Intervention: Nonhypothermic patients (oral body temperature ≥35.8 degrees C)
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Hypothermic patients
Number of subjects: 319
Study: 15387206

Group type: EXPERIMENTAL
Intervention: Alcoholics Anonymous (AA) affiliation composite scale including AA attendance, sum of steps completed, and identifying self as an AA member
Number of subjects: 1506

Group type: EXPERIMENTAL
Intervention: Three-item AA affiliation scale
Number of subjects: 1506
Study: 11314621

Group type: EXPERIMENTAL
Intervention: Intravenous patient‐controlled analgesia (nalbuphine HCl and ketorolac tromethamine)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional pethidine HCl intramuscular group
Number of subjects: 30
Study: 9146938

Group type: EXPERIMENTAL
Intervention: Topical azelastine (0.254 mg per nasal cavity)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral cetirizine (10 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7712967

Group type: EXPERIMENTAL
Intervention: Sclerotherapy
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control
Number of subjects: 89
Study: 29249140

Group type: EXPERIMENTAL
Intervention: Experimental Group 1 (EG1) - water gymnastics classes with emphasis on lower limb exercises for 12 weeks
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Experimental Group 2 (EG2) - conventional hydrogymnastics classes for 12 weeks
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control Group (CG) - no exercise during the 12 weeks
Number of subjects: 90
Study: 29231763

Group type: EXPERIMENTAL
Intervention: nVNS
Number of subjects: 92

Group type: COMPARATOR
Intervention: sham
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: nVNS (eCH subgroup)
Number of subjects: 92

Group type: COMPARATOR
Intervention: sham (eCH subgroup)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: nVNS (cCH subgroup)
Number of subjects: 92

Group type: COMPARATOR
Intervention: sham (cCH subgroup)
Number of subjects: 92
Study: 27009758

Group type: COMPARATOR
Intervention: 11-cm short sheath (Group A)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 45-cm long sheath (Group B)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 52
Study: 24147933

Group type: EXPERIMENTAL
Intervention: ATX‐101 (1 mg cm(‐2))
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: ATX‐101 (2 mg cm(‐2))
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: ATX‐101
Number of subjects: 363

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 363
Study: 22571072

Group type: EXPERIMENTAL
Intervention: Structured information (short video about practical aspects of the hospital stay, surgical and adjuvant treatment)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Routine informed consent only
Number of subjects: 60
Study: 20154074

Group type: EXPERIMENTAL
Intervention: 100% nitrogen through a 40% venturi mask at a flow rate of 10 L/min for 2 h
Number of subjects: 20

Group type: COMPARATOR
Intervention: Medical air
Number of subjects: 20
Study: 18421054

Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 1401

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1401
Study: 16643574

Group type: EXPERIMENTAL
Intervention: Intensive patient education
Number of subjects: 100

Group type: COMPARATOR
Intervention: Routine medical management only
Number of subjects: 100
Study: 14661284

Group type: EXPERIMENTAL
Intervention: Patients informed about adverse effects of contrast material
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Uninformed patients waiting for i.v. contrast material injection
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Uninformed patients undergoing unenhanced CT examination
Number of subjects: 297
Study: 10749632

Group type: EXPERIMENTAL
Intervention: Porous biphasic calcium phosphate ceramic blocks comprising hydroxyapatite and tricalcium phosphate
Number of subjects: 58

Group type: COMPARATOR
Intervention: Local bone grafts combined with autogenous iliac bone grafts
Number of subjects: 58